Biopharma Pulse - 2/7-2/11 Week in Review

As February begins, we review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and categories on BPIQ.com compared to XBI.

Table 1. BPIQ company weekly moves and YTD moves

Highlights for the week of 2/7 - 2/11

Biggest positive moves

• $CPRX +41% FDA Marketing Approval Previously Granted for Ruzurgi® (competitor) is No Longer Valid

Biggest negative moves

• $PRQR -75% Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10.

Additional big moves

• $KPTI -20.0% Karyopharm Reports Strong Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress. source

• $GMDA +16.8% Gamida Cell Initiates Rolling Submission of Biologics License Application for Omidubicel. source

• $ZSAN -48.6% Zosano Pharma Announces Pricing of $15.4 Million Public Offering of Common Stock and Warrants. source

Highlights for next week

• $SLGL PDUFA approval decision for EPSOLAY Cream with target date of 2/14/22.

• $AGIO PDUFA approval decision for Mitapivat with target date of 2/17/22, this is a Suspected Mover to Watch for February.

Watch over the next few weeks for quarterly company reports including commercial sales

See our Big Movers post to learn about the upcoming Feb Big Movers/Movers to Watch

#PRQR #CPRX #KPTI #GMDA #ZSAN #SLGL #AGIO